Partnering and licensing have become paramount in a pharmaceutical industry that is under inordinate pressure to fill pipelines and increase the number of approved new molecular entities. This article discusses how Novartis has gone about addressing this issue.
The Bio-Pharma business model is undergoing radical changes. Over the last two decades, we have seen a number of changes as the biopharmaceutical industry has gradually become more willing to look externally and embrace the concept of outsourcing as it looks for new sources of discovery and innovation.
Many disapprove of science faculty at American universities procuring corporate ventures that support research, instead of primarily functioning as an instructor, mentor and basic researcher.